Vitamin D analogs: Novel therapeutic agents for cardiovascular disease?

Current Opinion in Investigational Drugs

Volumn 5, Issue 9, 2004, Pages 947-951

  Reinhart, Glenn A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Blood pressure; Renin angiotensin; Vitamin D; Vitamin D receptor

Indexed keywords

CARDIOVASCULAR AGENT; COLECALCIFEROL; DRUG DERIVATIVE; PARATHYROID HORMONE;

ANIMAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HUMAN; HYPERTENSION; PHYSIOLOGY; REVIEW; SECRETION;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHOLECALCIFEROL; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; PARATHYROID HORMONE;

EID: 16644376463     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Reichel H, Koeffler P, Norman AW: The role of the vitamin D endocrine system in health and disease. N Engl J Med (1989) 320(15):980-991.
2. DeLuca HF, Krisinger J, Darwish H: The vitamin D system: 1990. Kidney Int (1990) 38(Suppl 29):S2-S8.
3. 3 of transcription of the pre-proparathyroid hormone gene. Endocrinology (1986) 119(6):2864-2866.
4. Mellanby E: An experimental investigation on rickets. Lancet (1919) 1:407-412.
5. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl (1999) 73:S14-S19.
6. Martin KJ, Gonzalez EA: Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis (2001) 38(5 Suppl 5):S34-S40.
7. Brown AJ: Therapeutic uses of vitamin D analogues. Am J Kidney Dis (2001) 38(5 Suppl 5):S3-S19.
8. Brown AJ, Dusso A, Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol (1999) 277(2 Pt 2):F157-F175.
9. Sutton ALM, MacDonald PN: Vitamin D: More than a "bone-a- fide" hormone. Mol Endocrinol (2003) 17(5):777-791.
10. Henry HL: Vitamin D hydroxylases. J Cell Biochem (1992) 49(1):4-9.
11. 3 1α-hydroxylase and vitamin D synthesis. Science (1997) 277 (5333):1827-1830.
12. White P, Cooke N: The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab (2000) 11(8):320-327.
13. McDonnell DP, Mangelsdorf DJ, Pike JW, Haussler MR, O'Malley BW: Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science (1987) 235(4793):1214-1217.
14. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, O'Malley BW: Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA (1988) 85(10):3294-3298.
15. Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell (1995) 83(6):841-850.
16. Norman AW, Mizwicki MT, Norman DPG: Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model.Nat Rev Drug Disc (2004) 3(1):27-41.
17. Christakos S, Dhawan P, Liu Y, Peng X, Porta A: New insights into the mechanisms of vitamin D action. J Cell Biochem (2003) 88(4):695-705.
18. McCarron DA: Is calcium more important than sodium in the pathogenesis of essential hypertension? Hypertension (1985) 7(4):607-627.
19. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int (1999) 56(2):383-392.
20. Helwig J-J, Musso M-J, Judes C, Nickols GA: Parathyroid hormone and calcium: Interactions in the control of renin secretion in the isolated, nonfiltering rat kidney. Endocrinology (1991) 129(3):1233- 1242.
21. Saussine C, Massfelder T, Parnin F, Judes C, Simeoni U, Helwig J-J: Renin stimulating properties of parathyroid hormone-related peptide in the isolated perfused rat kidney. Kidney Int (1993) 44(4):764-773.
22. Jespersen B, Randlov A, Abrahamsen J, Fogh-Andersen N, Kanstrup I-L: Effects of PTH(1-34) on blood pressure, renal function and hormones in essential hypertension: The altered pattern of reactivity may counteract raised blood pressure. Am J Hypertension (1997) 10(12Pt1):1356-1367.
23. Massfelder T, Helwig J-J: The parathyroid hormone-related protein system: More data but more unsolved questions. Curr Opin Nephrol Hypertens (2003) 12(1):35-42.
24. Cutler JA, Brittain E: Calcium and blood pressure. An epidemiologic perspective. Am J Hypertens (1990) 3(8 Pt 2):137S-146S.
25. 3 and its relation to physical activity and other heart disease risk factors in the general population. Ann Epidemiol (1992) 2(5):697-703.
26. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S: Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens (1995) 8(9):894-901.
27. Kristal-Boneh E, Froom P, Harari G, Ribak J: Association of calcitriol and blood pressure in normotensive men. Hypertension (1997) 30(5):1289-1294.
28. Lind L, Lithell H, Skarfors E, Wide L, Ljunghall S: Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance. Acta Med Scand (1988) 223(3):211-217.
29. Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM: Ultraviolet B and blood pressure. Lancet (1998) 352(9129):709-710.
30. Lind L, Wengle B, Wide L, Ljunghall S: Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am J Hypertension (1989) 2(1):20-25.
31. 3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab (2001) 86(4):1633-1637.
32. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, McMahon DJ: Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med (1997) 103(3):197-207.
33. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P: Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol (2003) 41(1):105-112.
34. Park CW, Oh YS, Shin YS, Kim C-M, Kim Y-S, Kim SY, Choi EJ, Chang YS, Bang BK: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis (1999) 33(1)73-81.
35. 3 users in a haemodialysis population. Nephrol Dial Transplant (2004) 19(1):179-184.
36. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paracalcitol or calcitriol therapy. N Engl J Med (2003) 349(5):446-456.
37. 3 is a negative regulator of the renin-angiotensin system. J Clin Invest (2002) 110(2):229-238.
38. Kong J, Li YC: Effects of Ang II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. Am J Physiol Regul Integr Comp Physiol (2003) 285(1):R255-R261.
39. 3. J Biol Chem (1994) 269(7):4934-4939.
40. 3 and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest (1996) 97(7):1577-1588.
41. Wu-Wong JR, Tian J, Goltzman D: Vitamin D analogs as therapeutic agents: A clinical study update. Curr Opin Invest Drugs (2004) 5(3):320-326.